CCNE1 and serous adenocarcinoma: Our analysis revealed that CCNE1 amplification occurred in 8.01% of ovarian cancer patients, with the highest frequency observed in carcinosarcoma patients (12.46%), followed by high-grade serous carcinoma patients (HGSOC patients, 9.84%).